



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Giandomenico Russo and Carlo M. Croce  
Application No.: 09/441,242 Group Art Unit: 1636  
Filed: November 16, 1999 Examiner: Gerald G. Leffers, Jr., Ph.D.  
Confirmation No.: 4066  
Title: TCL-1 GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
11/26/05	Donna Boudreau
Date	Signature
Donna Boudreau	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application file.

(Filed after payment of issue fee)

180.00 UP

07/28/2005 SSITH11 00000074 09441242

02 FC:1806

Statement Under 37 CFR 1.97(e)

- [ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- [ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

- [X] Copies of the cited references, B1, B2, C1 and C2, are enclosed.
  - [ ] Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
  - [ ] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- [X] The listed references, B1, B2, C1 and C2, were cited in the enclosed International Search Report in a counterpart foreign application.
- [ ] The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
  - [ ] the explanation provided on the attached sheet.
  - [ ] the explanation provided in the Specification.
  - [ ] submission of the enclosed International Search Report.
  - [ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
  - [ ] the enclosed English language abstract.

[ ] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ Examiner

\_\_\_\_ Date

- [ ] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- [ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

#### REMARKS


The enclosed International Search Report from the corresponding PCT application included the citation "Pharmacia P-L Biochemicals 1984 Product Reference Guide, issued 1984 by Pharmacia P-L Biochemicals, pages 35-37, see entire document." Our file, which was transferred from prior counsel, does not contain a copy of this document. Furthermore, we have not been able to obtain a copy of this reference through our own efforts. It is requested that the information disclosed herein be made of record in this application. A copy of this reference should be available in the filewrapper of PCT Application No.: PCT/US95/13663.

Method of payment:

- [X] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By   
Eric M. Balicky, Ph.D.  
Registration No.: 57,020  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

*July 26, 2005*

PTO-1449 REPRODUCED


INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION

June 28, 2005

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
3589.1017-001APPLICATION NO.  
09/441,242FIRST NAMED INVENTOR  
Giandomenico RussoFILING DATE  
11/16/1999EXAMINER  
Gerald G. Leffers, Jr., Ph.D.CONFIRMATION NO.  
4066GROUP  
1636

JUL 28 2005



## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES      NO
	B1	WO 93/13119	07-08-1993	Brigham and Women's Hospital	
	B2	WO 93/16178	08-19-1993	The United States of America, as represented by The Secretary, Dept. of Health and Human Services	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

C1	Uhlmann, E. and Peyman, A., "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90(4): 543-584 (1990).
C2	Wallace, R.B., and Miyada, C. G., "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries," in <i>Guide to Molecular Cloning Techniques, Methods in Enzymology</i> , Vol 152 (S.L. Berger and A.R. Kimmel, Eds.) New York: Academic Press, 1987, pages 432-442.

EXAMINER

DATE CONSIDERED